Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

456162

registered interest
date	29/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions NICE has had with the EU institutions on the proposed Joint Action 3 on health technology appraisals.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	28815
answer	answer is ministerial correction date of answer 08/03/2016 answer text <p>In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).</p><p> </p><p>NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.</p><p> </p><p>The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 28816 28817 question first answered 08/03/2016 11:38:59 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

456164

registered interest
date	29/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what representations he has received from NICE on the potential merits of a European relative effectiveness assessment to inform health technology appraisals.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	28816
answer	answer is ministerial correction date of answer 08/03/2016 answer text <p>In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).</p><p> </p><p>NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.</p><p> </p><p>The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 28815 28817 question first answered 08/03/2016 11:38:59 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

456165

registered interest
date	29/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NICE on its policy on a European relative effectiveness assessment for new drugs.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	28817
answer	answer is ministerial correction date of answer 08/03/2016 answer text <p>In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).</p><p> </p><p>NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.</p><p> </p><p>The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 28815 28816 question first answered 08/03/2016 11:38:59 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

453757

registered interest
date	22/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if NHS England will issue a consultation on a new Prioritisation Framework for making decisions on investment in specialised services and highly specialised services.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	27820
answer	answer is ministerial correction date of answer 01/03/2016 answer text <p>In its response to the public consultation &quot;Investing in Specialised Services&quot; in June 2015, NHS England described the work planned to further develop a prioritisation framework for specialised services. This document stated that NHS England will ensure there is proper stakeholder engagement, potentially including a short formal consultation.</p><p> </p><p>NHS England is currently testing a potential method for prioritisation for use in the 2016/17 business planning round, and will decide if a formal consultation is appropriate as part of this process.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/03/2016 10:52:00 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

453758

registered interest
date	22/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS England
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans NHS England has to involve NICE in the specialised commissioning policy development process.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	27782
answer	answer is ministerial correction date of answer 01/03/2016 answer text <p>NHS England is in discussions with the National Institute for Health and Care Excellence in relation to two areas of potential support to its clinical commissioning policy development process for directly commissioned specialised services from 2016/17.</p><p> </p><p>The first is the delivery of rapid evidence reviews (systematic reviews of the available evidence of clinical effectiveness for particular treatments and indications). The second is the production of commissioning support documents for licenced drugs which NHS England commissions directly.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/03/2016 10:50:07 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

453759

registered interest
date	22/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS England
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if NHS England will publish a list of the commissioning policies scheduled to be developed in (a) 2015-16, (b) 2016-17 and (c) 2017-18.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	27791
answer	answer is ministerial correction date of answer 01/03/2016 answer text <p>There are no plans for NHS England to publish the list of clinical policies in development.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/03/2016 10:59:12 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

453762

registered interest
date	22/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS England
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if NHS England will publish the (a) agendas and (b) minutes of all future meetings of the (i) Clinical Advisory Group and (ii) Specialised Commissioning Committee within a reasonable period after each such meeting takes place.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	27792
answer	answer is ministerial correction date of answer 01/03/2016 answer text <p>The specialised services commissioning committee provides regular updates of its business to NHS England's public board, of which a summary is published online.</p><p> </p><p>NHS England is considering how to further improve transparency, while not inhibiting the free and frank exchange of views.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/03/2016 10:57:42 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

442985

registered interest
date	06/01/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cystic Fibrosis and Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to paragraph 10 of NHS England's board paper, Allocation of resources to NHS England and the commissioning sector for 2016/17 to 2020/21, reference PB.17.12.15/04, if he will quantify the legally binding funding pressures regarding the introduction of treatments for (a) hepatitis C and (b) cystic fibrosis in 2016-17; and if he will make a statement.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	21387
answer	answer is ministerial correction date of answer 14/01/2016 answer text <p>NHS England has estimated a range for the impact of implementing planned and published National Institute for Health and Care Excellence Guidance relating to treatments for hepatitis C and cystic fibrosis. Due to the commercial in confidence agreements in place a specific figure cannot be provided at this time.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/01/2016 12:46:51 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

422640

registered interest
date	20/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, what assessment his Department has made of the date on which he will issue a tender for extended half-life products.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	12557
answer	answer is ministerial correction date of answer 30/10/2015 answer text <p>The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.</p><br /><p>NHS England has made no decision to develop a clinical commissioning policy for 'extended half-life products'. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.</p><br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 12558 question first answered 30/10/2015 12:05:33 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

422641

registered interest
date	20/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, when NHS England plans to take a decision on the development of a clinical commissioning policy for extended half-life products; what discussions NHS England has had to date on such a clinical commissioning policy; and if he will make a statement.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	12558
answer	answer is ministerial correction date of answer 30/10/2015 answer text <p>The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.</p><br /><p>NHS England has made no decision to develop a clinical commissioning policy for 'extended half-life products'. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.</p><br /> <br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 12557 question first answered 30/10/2015 12:05:33 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen